Genmab announced the approval of EPKINLYTM (epcoritamab) by the Japan Ministry of Health, Labour and Welfare, marking a significant advancement in the treatment of certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in adult patients who have undergone two or more lines of systemic therapy.
Epcoritamab is a bispecific antibody of the IgG1 class, developed using Genmab's proprietary DuoBody® technology. This technology, specifically DuoBody-CD3, is engineered to selectively direct cytotoxic T cells to target specific cell types, triggering an immune response.
EPKINLY is designed to bind to CD3 on T cells and CD20 on B cells. This unique dual binding capability enables EPKINLY to induce T-cell mediated killing of CD20+ cells, primarily B cells.
The approval of EPKINLY in Japan is based on the results from two open-label, multi-centre studies that were specifically designed to assess the safety and initial effectiveness of EPKINLY when administered as monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
The approval of EPKINLY in Japan addresses a significant unmet medical need, offering a new therapeutic option for adult patients with R/R LBCL who have exhausted other treatment options.
Despite advancements in LBCL treatment, the prognosis for patients with relapsed or refractory LBCL remains generally poor. EPKINLY's innovative mechanism of action and administration via subcutaneous injection provide hope for improved outcomes in this challenging medical condition.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!